Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy?

Prenatal Diagnosis

Volumn 20, Issue 4, 2000, Pages 311-317

  Spencer, Kevin ^a   Berry, Esther ^b   Crossley, Jennifer A ^b   Aitken, David A ^b   Nicolaides, Kypros H ^c  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b Medical Genetics   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL AGE; MATERNAL SERUM; NORMAL HUMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; TRISOMY 21;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A;

EID: 0034108953     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0223(200004)20:4<311::AID-PD809>3.0.CO;2-P     Document Type: Article

References (42)

1. Aitken DA, McGaw G, Crossley JA, Berry E, Connor JM, Spencer K, Macri JN. 1993. First trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. Prenat Diagn 13: 681-689.
2. Berry E, Aitken DA, Crossley JA, Macri JN, Connor JN. 1997. Screening for Down syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynaecol 104: 811-817.
3. Biagiotti R, Cariati E, Brizzi L, D'Agata A. 1995. Maternal serum screening for Down's syndrome in the first trimester. Br J Obstet Gynaecol 102: 660-662.
4. Bogart M, Golbus M, Sorg N, Jones OW. 1989. Human chorionic gonadotropin levels in pregnancies with aneuploid fetuses. Prenat Diagn 9: 379-384.
5. Brambati B, Lanzani A, Tului L. 1991. Ultrasound and biochemical assessment of first trimester pregnancy. In The Embryo: Normal and Abnormal Development and Growth, Chapman M, Grudzinskas JG, Chard T (eds). Springer-Verlag: New York; 181-194.
6. Brizot ML, Snijders RJM, Butler J, Bersinger NA, Nicolaides KH. 1995. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 102: 127-132.
7. Brock DJH, Barron L, Holloway S, Liston WA, Hillier SG, Seppala M. 1990. First trimester maternal serum biochemical indicators in Down's syndrome. Prenat Diagn 10: 245-251.
8. Casals E, Aibar C, Martinez JM, Borrel A, Soler A, Ojuel J, Ballesta AM, Fortuny A. 1999. First trimester biochemical markers for Down syndrome. Prenat Diagn 19: 8-11.
9. 3 and hCG between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities. Am J Obstet Gynecol 168: 1864-1869.
10. Crossley JA, Aitken DA, Berry E, Connor JM. 1994. Impact of a regional screening programme using serum alpha fetoprolein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland. J Med Screen 1: 80-83.
11. Cuckle HS, Wald NJ, Barkai G, Fuhrmann W, Altland K, Brambati B, Knight G, Palomaki G, Haddow JE, Canick J. 1988. First trimester biochemical screening for Down's syndrome. Lancet ii: 851-852.
12. Cuckle HS, Ellis AR, Seth J. 1995. Provision of screening for Down's syndrome. Br Med J 311: 512.
13. Forest JC, Masse J, Rousseau F, Moutquin JM, Brideau NA, Belanger M. 1995. Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. Clin Biochem 28: 443-449.
14. Goodburn SF, Yates JRW, Raggatt PR. 1994. Second trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin and unconjugated oestriol: experience of a regional programme. Prenat Diagn 14: 391-402.
15. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. 1998. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 338: 955-961.
16. Hallahan T, Krantz D, Khabbaza E, Orlandi F, Rossi C, Curcio P, Macri S, Larsen J, Buchanan P, Macri J. 1998. First trimester maternal serum screening for Down syndrome: intact hCG versus free beta hCG. Am J Hum Genet 63 (Suppl): A164.
17. Hogdall CK, Hogdall EVS, Arends J, Noorgard-Pedersen B, Smidt-Jensen S, Larsen SO. 1992. CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters. Prenal Diagn 12: 223-227.
18. Isles RK, Sharma K, Wathen NC, Campbell J, Ward H, Muller F, Grudzinskas JG, Chard T. 1993. hCG, free subunit and PAPP-A composition of maternal serum in normal and Down's syndrome pregnancies. Fourth Conference: Endocrinology and Metabolism in Human Reproduction. Royal College of Obstetrics and Gynaecology: London.
19. Johnson A, Cowchock FS, Darby M, Wapner R, Jackson LG. 1991. First trimester maternal serum AFP and hCG in aneuploid pregnancies. Prenat Diagn 11: 443-450.
20. 3 hCG and free beta-hCG measurements in unaffected and affected pregnancies with fetal Down syndrome. Am J Hum Genet 55 (Suppl): A281.
21. Kratzer PG, Golbus MS, Monroe SE, Finkelstein DE, Taylor RN. 1991. First trimester aneuploidy screening using serum human chorionic gonadotropin (hCG), free alpha-hCG and progesterone. Prenal Diagn 11: 751-765.
22. Macintosh MCM, Iles R, Teisner B, Sharma K, Chard T, Grudzinskas JG, Ward RH, Muller F. 1994. Maternal serum hCG and PAPP-A markers for fetal Down syndrome at 8 14 weeks. Prenat Diagn 14: 203-208.
23. Macri JN, Spencer K. 1996. Towards the optimal protocol for Down's syndrome screening. Am J Obstet Gynecol 174: 1668-1669.
24. Office of Population Censuses and Surveys. 1994. Birth Statistics 1986-1994. Series FM1, Nos 13 21. HMSO: London.
25. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. 1997. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 176: 1046-1051.
26. Reynolds TM, Dunstan F, Nix B, Williams K, Crossley J, Holding S, Krantz D, Wright D, Bray I, Spencer K. 1998. Combining ultrasound and biochemistry in first trimester screening for Down's syndrome. Response to Wald and Hackshaw. Prenat Diagn 18: 511-515.
27. Royston P, Thompson SG. 1992. Model based screening for risk with application to Down's syndrome. Stats Med 11: 257-268.
28. Snijders RJM, Sebire NJ, Nicolaides KH. 1995. Maternal age and gestational age specific risk for chromosomal defects. Fetal Diagn Ther 10: 356-357.
29. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH , for the Fetal Medicine Foundation First Trimester Screening Group. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10 14 weeks of gestation. Lancet 351: 343-346.
30. Spencer K. 1997. hCG and it subunits in first trimester Down syndrome screening. In Screening for Down Syndrome in the First Trimester, Grudzinskas JG, Ward RHT (eds). RCOG Press: London; 117-131.
31. Spencer K. 1999a. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven-year review. Br J Obstet Gynaecol 106: 1287-1293.
32. Spencer K. 1999b. One stop clinic for assessment of risk for fetal abnormalities. Downs Screening News 6: 10.
33. Spencer K, Macri JN, Aitken DA, Connor JM. 1992. Free beta-hCG as a first trimester marker for fetal trisomy. Lancet 339: 1480.
34. Spencer K, Macri JN, Anderson RW, Aitken DA, Berry E, Crossley JA, Wood PJ, Coombes EJ, Stroud M, Worthington DJ, Doran J, Barbour H, Wilmot R. 1993. Dual analyte immunoassay in neural tube defect and Down's syndrome screening: results of a multicentrc clinical trial. Ann Clin Biochem 30: 394-401.
35. Spencer K, Aitken DA, Crossley JA, McGaw G, Berry E, Anderson R, Connor JM, Macri JN. 1994. First trimester biochemistry screening for trisomy 21: the role of free beta hCG, alpha fctoprotein and pregnancy associated plasma protein A. Ann Clin Biochem 31: 447-454.
36. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999a. A screening program for trisomy 21 at 10 14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
37. Spencer K, Crossley JA, Green K, Worthington DJ, Brownbill K, Ailken DA. 1999b. Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18. Prenat Diagn 19: 1127-1134.
38. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. 1999. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10 14 weeks of gestation. Prenat Diagn 19: 1035-1042.
39. Van Lith JMM. 1992. First trimester maternal serum hCG as a marker for fetal chromosomal disorders. Prenat Diagn 12: 495-504.
40. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. 1992. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 305: 391-394.
41. Wald NJ, George L, Smith D, Densem JW, Petterson K, on behalf of the International Prenatal Screening Research Group. 1996. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 104: 407-412.
42. Wald NJ, Kennard A, Hackshaw A, McGuire A. 1997. Antenatal screening for Down's syndrome. J Medical Screening 4: 181-246.